The physiology of GLP-1 is discussed as well as its mechanisms of actions in obesity, in particular, the role of sensory afferents and GLP-1 receptors in the brain
Most of it resolves as the dose titrates
A clinical study at the University of Pisa found that 80% of PCOS (now PMOS) patients on semaglutide (the active ingredient in Wegovy) achieved at least 5% weight loss
Limitations Side effects can be more pronounced initially (nausea, diarrhea)
[4] Most dehydration issues happen in the first few weeks after starting or increasing your dose, since this is when nausea and vomiting are usually the strongest
Sample Size Based on previously published studies, we estimated a 0.5% and 7% rate of clinically significant RGV in nonusers of GLP-1 and GIP agonists vs users who do not hold the medications prior to the procedure, respectively